HCPLive

08/31/2025

Watch Albert Rizzo, MD, and James Chalmers, MBChB, discuss brensocatib's milestone entry into the market for bronchiectasis now:

In this video, the fourth in a 5-part series, panelists discuss who may benefit from brensocatib's approval.

08/31/2025

People with PBC and moderate-to-severe pruritus experience a greater health-related quality of life burden and reduced activity compared to those with mild-to-no pruritus, according to new research.

Learn more:

People with PBC and pruritus had a greater negative impact on HRQoL and reduced activity compared to those without pruritus, infrequently using medication.

08/30/2025

Up to 50% of patients with struggle with depression or anxiety. HCPLive interviewed dermatologists, psychiatric clinicians, and patients on psoriasis’ impact on mental health. https://hubs.li/Q03GgBhr0

08/30/2025

Jacob Sands, MD, joins Albert Rizzo, MD, to discuss the latest updates in treating small cell lung cancer in the latest episode. Watch now:

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

08/30/2025

ICYMI: The FDA approved an updated REMS labeling for sparsentan (Filspari) for the treatment of IgAN.

Learn more: https://hubs.li/Q03GgzhZ0

08/30/2025

Multi-omics profiling links regulatory T-cell activity, B-cell suppression, and gastrointestinal immune regulation to peanut oral immunotherapy success.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

08/30/2025

Brensocatib was well-tolerated in people with bronchiectasis in pivotal trials, with few infections and few cases of hyperkeratosis. Learn more about its safety profile now: https://hubs.li/Q03GgzSx0

08/29/2025

Combining salivary bacteria, serum inflammatory mediators, and past attack history predicts future severe asthma attacks with AUROCC ~0.87—outperforming conventional biomarkers.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

08/29/2025

The has issued a Complete Respones Letter to Outlook Therapeutics for ONS-5010, an investigative treatment for wet age-related macular degeneration. The company has announced plans to meet with the FDA to discuss a path forward.

Read more: https://hubs.li/Q03G62Fg0

08/29/2025

A Mediterranean diet, calorie reduction, and moderate physical activity combined may reduce type 2 diabetes risk by up to 1/3, based on recent research.

Read now:

Recent research has shown a reduction of nearly 1/3 in type 2 diabetes risk associated with adherence to a Mediterranean diet, calorie reduction, and moderate exercise.

08/29/2025

New research is shedding light on the benefits of adhering to a healthy diet and being physically active in the context of alcohol-attributable liver-related mortality risk.

Learn more: https://hubs.li/Q03G62700

08/29/2025

Based on the recently formulated PREVENT equations from the American Heart Association, just over 11 million Americans are eligible for statin treatment for ASCVD.

Read more:

A recent analysis utilizing the AHA’s PREVENT equations has found 11.8 million US adults aged 40 to 75 had a 10-year ASCVD risk of 5% or greater.